Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$13.69 +1.0%	$12.28	$5.10 ▼ $17.43	$1.01B	1.71	3.29 million shs	3.47 million shs
HCM HUTCHMED	$16.10 -0.1%	$16.42	$11.51 ▼ $21.50	$2.81B	0.55	49,358 shs	62,441 shs
RARE Ultragenyx Pharmaceutical	$29.78 +0.9%	$31.69	$25.81 ▼ $60.37	$2.84B	0.25	1.72 million shs	1.27 million shs
XENE Xenon Pharmaceuticals	$38.84 +1.7%	$33.16	$26.74 ▼ $46.00	$2.94B	1.16	1.06 million shs	1.19 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	+0.96%	+5.88%	+17.81%	+10.76%	+173.25%
HCM HUTCHMED	-0.06%	-2.13%	-8.37%	+20.15%	-10.21%
RARE Ultragenyx Pharmaceutical	+0.88%	+0.30%	+6.32%	-16.49%	-47.80%
XENE Xenon Pharmaceuticals	+1.73%	+1.60%	+24.53%	+30.55%	-0.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	2.6959 of 5 stars	3.4	1.0	0.0	3.3	0.0	1.9
HCM HUTCHMED	2.7194 of 5 stars	3.5	2.0	0.0	2.2	0.0	1.9
RARE Ultragenyx Pharmaceutical	4.7249 of 5 stars	4.5	3.0	3.8	3.3	2.5	0.6
XENE Xenon Pharmaceuticals	2.1011 of 5 stars	3.5	1.0	0.0	2.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.88	Moderate Buy	$16.71	22.09% Upside
HCM HUTCHMED	3.00	Buy	$28.00	73.91% Upside
RARE Ultragenyx Pharmaceutical	2.92	Moderate Buy	$81.50	173.67% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$53.20	36.97% Upside

Current Analyst Ratings Breakdown

Latest CRMD, HCM, RARE, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/12/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $55.00
8/12/2025	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00
8/11/2025	HCM HUTCHMED	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $17.00
8/8/2025	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$136.00 ➝ $128.00
8/6/2025	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$112.00 ➝ $105.00
7/28/2025	RARE Ultragenyx Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$80.00
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$43.47M	23.51	N/A	N/A	$2.96 per share	4.63
HCM HUTCHMED	$630.20M	4.46	$0.29 per share	56.09	$7.12 per share	2.26
RARE Ultragenyx Pharmaceutical	$560.23M	5.12	N/A	N/A	$1.57 per share	18.97
XENE Xenon Pharmaceuticals	$9.43M	317.60	N/A	N/A	$8.22 per share	4.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$17.93M	$0.75	18.25	14.56	N/A	42.11%	42.73%	34.19%	10/29/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	11.03	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.53	N/A	N/A	N/A	-87.34%	-237.48%	-37.66%	11/4/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.55	N/A	N/A	N/A	N/A	-38.50%	-36.47%	N/A

Latest CRMD, HCM, RARE, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	XENE Xenon Pharmaceuticals	-$1.03	-$1.07	-$0.04	-$1.07	N/A	N/A
8/7/2025	Q2 2025	CRMD CorMedix	$0.20	$0.28	+$0.08	$0.28	$29.88 million	$39.74 million
8/5/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	-$1.17	+$0.10	-$1.17	$161.37 million	$166.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	7.82	7.52
HCM HUTCHMED	0.05	4.65	4.51
RARE Ultragenyx Pharmaceutical	N/A	2.45	2.30
XENE Xenon Pharmaceuticals	N/A	15.14	15.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
HCM HUTCHMED	8.82%
RARE Ultragenyx Pharmaceutical	97.67%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	5.30%
HCM HUTCHMED	3.60%
RARE Ultragenyx Pharmaceutical	5.50%
XENE Xenon Pharmaceuticals	4.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	74.65 million	70.69 million	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
RARE Ultragenyx Pharmaceutical	1,294	96.37 million	91.07 million	Optionable
XENE Xenon Pharmaceuticals	210	77.11 million	73.97 million	Optionable

CRMD, HCM, RARE, and XENE Headlines

Recent News About These Companies

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Algert Global LLC

August 22 at 4:43 AM | marketbeat.com

An Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 44% Undervalued

August 21 at 8:14 AM | finance.yahoo.com

Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Aberdeen Group plc

August 21 at 4:18 AM | marketbeat.com

Lord Abbett & CO. LLC Sells 106,990 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

August 19, 2025 | marketbeat.com

What is Chardan Capital's Forecast for XENE FY2025 Earnings?

August 19, 2025 | marketbeat.com

FY2025 Earnings Estimate for XENE Issued By Chardan Capital

August 18, 2025 | americanbankingnews.com

XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald

August 16, 2025 | marketbeat.com

HC Wainwright Analysts Decrease Earnings Estimates for XENE

August 16, 2025 | marketbeat.com

Q3 EPS Estimate for Xenon Pharmaceuticals Lifted by Analyst

August 16, 2025 | marketbeat.com

William Blair Has Negative Estimate for XENE Q3 Earnings

August 16, 2025 | marketbeat.com

Q3 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst

August 16, 2025 | americanbankingnews.com

Leerink Partnrs Issues Positive Outlook for XENE Earnings

August 16, 2025 | americanbankingnews.com

William Blair Has Pessimistic Outlook of XENE Q3 Earnings

August 16, 2025 | americanbankingnews.com

What is William Blair's Estimate for XENE FY2027 Earnings?

August 15, 2025 | marketbeat.com

Xenon Pharmaceuticals' (XENE) "Buy" Rating Reiterated at Chardan Capital

August 14, 2025 | marketbeat.com

Chardan Capital Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

August 14, 2025 | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up After Analyst Upgrade

August 13, 2025 | marketbeat.com

Royal Bank Of Canada Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

August 13, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Given New $43.00 Price Target at Wedbush

August 13, 2025 | marketbeat.com

Wedbush Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

August 13, 2025 | americanbankingnews.com

TD Cowen Reaffirms Their Buy Rating on Xenon (XENE)

August 13, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CRMD, HCM, RARE, and XENE Company Descriptions

CorMedix NASDAQ:CRMD

$13.69 +0.13 (+0.96%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$13.85 +0.16 (+1.17%)

As of 08/22/2025 07:37 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

HUTCHMED NASDAQ:HCM

$16.10 -0.01 (-0.06%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$16.10 0.00 (0.00%)

As of 08/22/2025 04:10 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Ultragenyx Pharmaceutical NASDAQ:RARE

$29.78 +0.26 (+0.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$29.90 +0.13 (+0.42%)

As of 08/22/2025 07:08 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Xenon Pharmaceuticals NASDAQ:XENE

$38.84 +0.66 (+1.73%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$38.84 0.00 (0.00%)

As of 08/22/2025 07:32 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time